Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome

NCT03557788 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT03557788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03557788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome
Lead sponsor
National University Hospital, Singapore
Phase
Phase 4
Overall status
Completed
Start date
May 7, 2018
Completion date
August 13, 2021
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome with diarrhea